Skip to main content

Table 2 Survival Hazard Ratio (HR) calculated according to expression values of 9 ICR molecules (only HR ≤ 0.7 ≥ 1.5 are reported)

From: Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies

 

Cancer type

OX40 (TNFRSF4)

TIM3 (HAVCR2)

PD-1 (PDCD1)

4-1BB (TNFRSF9)

TIGIT

LAG3

GITR (TNFRSF18)

CTLA4

PD-L1 (CD274)

Horizontal Summary

1

SKCM

0.59

0.54

0.57

0.59

0.56

0.52

0.58

0.63

0.56

9/9

2

TGCT

3.1

 > 10

2

 > 10

2

2

4.2

 > 10

 > 10

9/9

3

THYM

2.9

3

0.47

1.5

 > 10

6.1

2.2

5

7.6

9/9

4

LGG

1.7

1.7

1.9

1.5

 

1.6

 

1.8

1.8

7/9

5

KIRC

 

0.68

   

1.5

1.9

1.5

0.62

5/9

6

READ

  

0.58

0.63

0.67

 

0.68

0.61

 

5/9

7

UCEC

 

0.44

0.43

0.47

0.5

  

0.62

 

5/9

8

ACC

1.5

0.52

  

0.56

2.2

 

0.65

 

5/9

9

DLBC

 

0.52

0.6

0.69

    

1.6

4/9

10

KICH

1.6

0.34

0.69

   

0.48

  

4/9

11

PCPG

0.58

  

2.8

  

0.17

0.48

 

4/9

12

KIRP

2.1

0.49

 

2.5

 

1.7

   

4/9

13

BRCA

  

0.65

 

0.66

 

0.67

  

3/9

14

CESC

0.61

0.67

  

0.53

    

3/9

15

CHOL

 

0.47

 

0.53

  

0.64

  

3/9

16

LAML

  

2.2

  

1.8

  

1.7

3/9

17

PRAD

0.53

   

0.39

   

0.62

3/9

18

HNSC

0.58

   

0.63

    

2/9

19

THCA

1.6

 

0.5

      

2/9

20

ESCA

     

1.5

   

1/9

21

GBM

   

1.5

     

1/9

22

LIHC

1.6

        

1/9

23

PAAD

0.59

        

1/9

24

SARC

  

0.62

      

1/9

25

UCS

 

0.67

       

1/9

26

BLCA

         

0/9

27

COAD

         

0/9

28

LUAD

         

0/9

29

LUSC

         

0/9

30

OV

         

0/9

31

STAD

         

0/9

 

Vertical summary

14/31

13/31

12/31

11/31

10/31

9/31

9/31

9/31

8/31

Â